Immunotherapy Advances in Upfront SCAC Expose Need for Better Second-Line Strategies

Topline Data from PODIUM-303Adding retifanlimab to carboplatin and paclitaxel produced a superior median PFS of 9.3 months vs 7.4 months with chemotherapy alone, representing a 37% reduction in risk of progression (HR, 0.63; 95% CI, 0.47-0.84; P = .0006).The ORR increased to 55.8% with the triplet vs 44.2% with chemotherapy alone, and the median DOR nearly doubled to 14.0 months from 7.2 months with these respective regimens.The median OS was numerically longer with upfront retifanlimab, and toxicities were both manageable and consistent with other PD-1 inhibitors, supporting the combination as a first-line standard of care.